Export

EN
FR
Pegaspargase
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines
ATC codes: L01XX24
EMLc
Indication
Lymphoid leukaemia, not elsewhere classified ICD11 code: 2C03.3
INN
Pegaspargase
Medicine type
Biological agent
List type
Core (EML)
(EMLc)
Additional notes
Including quality-assured biosimilars
Formulations
Parenteral > General injections > IV: 3750 units per 5 mL in vial ; 3750 units in vial powder for injection
EML status history
First added in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Pegaspargase
DrugBank
Pegaspargase
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of pegaspargase powder for injection 3750 units in vial to the EML and EMLc.